Search tips
Search criteria 


Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 2001 April; 84(8): 1016–1022.
PMCID: PMC2363867

Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer


Results of the proton magnetic resonance spectroscopy carried out on normal, benign breast disease and locally advanced breast cancer patients are presented. The in-vivo MR spectra of malignant breast tissue of patients (n = 67) suffering from infiltrating ductal carcinoma are dominated by the water resonance, while the spectra of the unaffected contralateral breast tissue of these patients are mainly dominated by resonance arising from lipids which is similar to the spectra of normal breast tissue obtained from volunteers (controls, n = 16). In addition to the water and lipid peaks, in majority of the patients (~80%) the water suppressed spectra showed a resonance at 3.2 ppm due to choline containing compounds (TCho) before treatment. In patients receiving neoadjuvant chemotherapy, absence/reduction in choline was observed in 89% of the patients. TCho was also observed in 2 of 14 benign lesions. The sensitivity and specificity of in-vivo MRS in detecting TCho in malignant tumours was 78% and 86%, respectively. Observation of TCho before treatment and its disappearance (or reduction) after treatment may be a useful indicator of response of locally advanced breast cancer to neoadjuvant chemotherapy. © 2001 Cancer Research Campaign

Keywords: in-vivo proton magnetic resonance spectroscopy (MRS), locally advanced breast cancer (LABC), neoadjuvant chemotherapy (NACT), preoperative chemotherapy, total choline (TCho)

Full Text

The Full Text of this article is available as a PDF (253K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Boné B, Péntek Z, Perbeck L, Veress B. Diagnostic accuracy of mammography and contrast-enhanced MR imaging in 238 histologically verified breast lesions. Acta Radiol. 1997 Jul;38(4 Pt 1):489–496. [PubMed]
  • Daniel BL, Yen YF, Glover GH, Ikeda DM, Birdwell RL, Sawyer-Glover AM, Black JW, Plevritis SK, Jeffrey SS, Herfkens RJ. Breast disease: dynamic spiral MR imaging. Radiology. 1998 Nov;209(2):499–509. [PubMed]
  • den Hollander JA, Luyten PR, Mariën AJ, Segebarth CM, Balériaux DF, de Beer R, van Ormondt D. Potentials of quantitative image-localized human 31P nuclear magnetic resonance spectroscopy in the clinical evaluation of intracranial tumors. Magn Reson Q. 1989 Apr;5(2):152–168. [PubMed]
  • Friedrich M. MRI of the breast: state of the art. Eur Radiol. 1998;8(5):707–725. [PubMed]
  • Glaholm J, Leach MO, Collins DJ, Mansi J, Sharp JC, Madden A, Smith IE, McCready VR. In-vivo 31P magnetic resonance spectroscopy for monitoring treatment response in breast cancer. Lancet. 1989 Jun 10;1(8650):1326–1327. [PubMed]
  • Goel AK, Seenu V, Shukla NK, Raina V. Breast cancer presentation at a regional cancer centre. Natl Med J India. 1995 Jan-Feb;8(1):6–9. [PubMed]
  • Gribbestad IS, Fjösne HE, Haugen OA, Nilsen G, Krane J, Petersen SB, Kvinnsland S. In vitro proton NMR spectroscopy of extracts from human breast tumours and non-involved breast tissue. Anticancer Res. 1993 Nov-Dec;13(6A):1973–1980. [PubMed]
  • Gribbestad IS, Singstad TE, Nilsen G, Fjøsne HE, Engan T, Haugen OA, Rinck PA. In vivo 1H MRS of normal breast and breast tumors using a dedicated double breast coil. J Magn Reson Imaging. 1998 Nov-Dec;8(6):1191–1197. [PubMed]
  • Harms SE, Flamig DP, Hesley KL, Meiches MD, Jensen RA, Evans WP, Savino DA, Wells RV. MR imaging of the breast with rotating delivery of excitation off resonance: clinical experience with pathologic correlation. Radiology. 1993 May;187(2):493–501. [PubMed]
  • Heywang-Köbrunner SH, Viehweg P, Heinig A, Küchler C. Contrast-enhanced MRI of the breast: accuracy, value, controversies, solutions. Eur J Radiol. 1997 Feb;24(2):94–108. [PubMed]
  • Jagannathan NR, Singh M, Govindaraju V, Raghunathan P, Coshic O, Julka PK, Rath GK. Volume localized in vivo proton MR spectroscopy of breast carcinoma: variation of water-fat ratio in patients receiving chemotherapy. NMR Biomed. 1998 Nov;11(8):414–422. [PubMed]
  • Kaiser WA. MR-Mammographie. Radiologe. 1993 May;33(5):292–299. [PubMed]
  • Kasimos JN, Merchant TE, Gierke LW, Glonek T. 31P magnetic resonance spectroscopy of human colon cancer. Cancer Res. 1990 Feb 1;50(3):527–532. [PubMed]
  • Katz-Brull R, Margalit R, Bendel P, Degani H. Choline metabolism in breast cancer; 2H-, 13C- and 31P-NMR studies of cells and tumors. MAGMA. 1998 Aug;6(1):44–52. [PubMed]
  • Kvistad KA, Bakken IJ, Gribbestad IS, Ehrnholm B, Lundgren S, Fjøsne HE, Haraldseth O. Characterization of neoplastic and normal human breast tissues with in vivo (1)H MR spectroscopy. J Magn Reson Imaging. 1999 Aug;10(2):159–164. [PubMed]
  • Leach MO, Verrill M, Glaholm J, Smith TA, Collins DJ, Payne GS, Sharp JC, Ronen SM, McCready VR, Powles TJ, et al. Measurements of human breast cancer using magnetic resonance spectroscopy: a review of clinical measurements and a report of localized 31P measurements of response to treatment. NMR Biomed. 1998 Nov;11(7):314–340. [PubMed]
  • Mackinnon WB, Barry PA, Malycha PL, Gillett DJ, Russell P, Lean CL, Doran ST, Barraclough BH, Bilous M, Mountford CE. Fine-needle biopsy specimens of benign breast lesions distinguished from invasive cancer ex vivo with proton MR spectroscopy. Radiology. 1997 Sep;204(3):661–666. [PubMed]
  • Merchant TE, Gierke LW, Meneses P, Glonek T. 31P magnetic resonance spectroscopic profiles of neoplastic human breast tissues. Cancer Res. 1988 Sep 15;48(18):5112–5118. [PubMed]
  • Orel SG. High-resolution MR imaging for the detection, diagnosis, and staging of breast cancer. Radiographics. 1998 Jul-Aug;18(4):903–912. [PubMed]
  • Orel SG, Hochman MG, Schnall MD, Reynolds C, Sullivan DC. High-resolution MR imaging of the breast: clinical context. Radiographics. 1996 Nov;16(6):1385–1401. [PubMed]
  • Piccoli CW. Contrast-enhanced breast MRI: factors affecting sensitivity and specificity. Eur Radiol. 1997;7 (Suppl 5):281–288. [PubMed]
  • Roebuck JR, Cecil KM, Schnall MD, Lenkinski RE. Human breast lesions: characterization with proton MR spectroscopy. Radiology. 1998 Oct;209(1):269–275. [PubMed]
  • Sijens PE, Wijrdeman HK, Moerland MA, Bakker CJ, Vermeulen JW, Luyten PR. Human breast cancer in vivo: H-1 and P-31 MR spectroscopy at 1.5 T. Radiology. 1988 Dec;169(3):615–620. [PubMed]
  • Singer S, Souza K, Thilly WG. Pyruvate utilization, phosphocholine and adenosine triphosphate (ATP) are markers of human breast tumor progression: a 31P- and 13C-nuclear magnetic resonance (NMR) spectroscopy study. Cancer Res. 1995 Nov 15;55(22):5140–5145. [PubMed]
  • Smith TA, Eccles S, Ormerod MG, Tombs AJ, Titley JC, Leach MO. The phosphocholine and glycerophosphocholine content of an oestrogen-sensitive rat mammary tumour correlates strongly with growth rate. Br J Cancer. 1991 Nov;64(5):821–826. [PMC free article] [PubMed]
  • Twelves CJ, Porter DA, Lowry M, Dobbs NA, Graves PE, Smith MA, Rubens RD, Richards MA. Phosphorus-31 metabolism of post-menopausal breast cancer studied in vivo by magnetic resonance spectroscopy. Br J Cancer. 1994 Jun;69(6):1151–1156. [PMC free article] [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK